| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7235247 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(5 years ago) | |
| US6939559 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(5 years ago) | |
| US8383611 | COVIS | Ciclesonide containing aqueous pharmaceutical composition |
Oct, 2020
(3 years ago) | |
| US6767901 | COVIS | Ciclesonide contained pharmaceutical composition for application to mucosa |
Oct, 2020
(3 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) | |
Omnaris is owned by Covis.
Omnaris contains Ciclesonide.
Omnaris has a total of 6 drug patents out of which 5 drug patents have expired.
Expired drug patents of Omnaris are:
- US7235247
- US6939559
- US8383611
- US6767901
- US5482934
Omnaris was authorised for market use on 20 October, 2006.
Omnaris is available in spray, metered;nasal dosage forms.
Omnaris can be used as treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults and adolescents 12 years of age and older, nasal treatment of seasonal and perennial allergic rhinitis symptoms.
Drug patent challenges can be filed against Omnaris from 20 October, 2010.
The generics of Omnaris are possible to be released after 01 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 20 October, 2006
Treatment: Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults a...
Dosage: SPRAY, METERED;NASAL
OMNARIS family patents
